唾液腺癌并不常见，并且由于其组织学多样性和不同的临床行为而构成挑战，使得为晚期或复发阶段选择最佳的全身治疗变得困难。本系统综述旨在评估四种唾液癌的总体生存结果和系统治疗反应。PubMed 和 Google Scholar 搜索发现了涉及接受系统治疗的最初晚期或复发病例的研究。根据系统评价和荟萃分析（PRISMA）清单的首选报告项目，选择具有关于治疗反应和结果的清晰、个性化数据的研究。在筛选的 723 项研究中，有 44 项符合我们的纳入标准。总共纳入了 426 例复发/转移性唾液腺癌，主要是唾液管癌 (SDC；n = 219) 和腺样囊肿癌 (ACC；n = 167) 。组织分子标记物与组织学密切相关，HER2 过度表达和雄激素受体核表达通常见于 SDC 和腺癌（未另行指定的病例），而 KIT 过度表达仅见于 ACC。缓解率与特定受体阻断相关，其中曲妥珠单抗联合化疗和比卡鲁胺最有效（总体缓解率分别为 80% 和 42.8%）。此外，对治疗的反应对总生存期产生积极影响（反应者中位生存期为 38 个月，无反应者为 18.7 个月；P < 0.001）。在对特定队列的回顾性分析中，每种组织学类型的生存结果表明，抗人表皮生长因子受体 2 疗法对 SDC 更有效，而化疗对 ACC 更有效。全身治疗有助于唾液腺患者的生存癌症处于复发或新进展阶段。对治疗的反应很大程度上受到组织学亚型和治疗特异性的影响。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Salivary gland cancers are infrequent and pose a challenge owing to their histological diversity and varied clinical behavior, making the selection of optimal systemic treatments for advanced or recurrent stages difficult. This systematic review aims to assess overall survival outcomes and systemic treatment responses across four types of salivary cancers.A PubMed and Google Scholar search identified studies involving initially advanced or relapsed cases undergoing systemic treatment. Studies with clear, individualized data on treatment responses and outcomes were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Of the 723 studies screened, 44 met our inclusion criteria.A total of 426 cases of recurrent/metastatic salivary gland cancer, mostly salivary duct carcinoma (SDC; n = 219) and adenoid cyst carcinoma (ACC; n = 167), were included. Histomolecular markers were heavily associated with histology, with HER2 overexpression and androgen receptor nuclear expression typically found in SDC and adenocarcinoma not otherwise specified cases and KIT overexpression only in ACC. The response rates were associated with specific receptor blockage, with trastuzumab plus chemotherapy, and bicalutamide being the most effective (overall response rate 80% and 42.8%, respectively). Moreover, the response to treatment positively influenced overall survival (responders 38 versus non-responders 18.7 median months; P < 0.001). In this retrospective analysis of a particular cohort, survival outcomes per histology types showed that anti-human epidermal growth factor receptor 2 therapy was more effective for SDC, while chemotherapy was more effective for ACC.Systemic treatments contribute to the survival of patients with salivary gland cancer at relapsed or newly advanced stages. The response to treatment is heavily influenced by histological subtype and treatment specificity.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.